24 completed, 8 recruiting, 6 unknown, 3 not yet recruiting. 13 Phase 4, 10 Phase 2, 6 Phase 3, 5 Not applicable, 5 Phase 1.
Follow Hypogonadism, Male: new trials by email Literature Review of Hypogonadism, Male trials Research Report on Hypogonadism, Male
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anticipated Stigma, Illness Identity, and Quality of Life in Male Hypogonadism Hypogonadism, Male, Endocrine Disease | Not yet recruiting | Hacettepe University | 90 | 2026-10-01 | 2026-08-07 | |
| Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance Testosterone cypionate - Prostate Cancer, Hypogonadism, Male | Phase 4 | Not yet recruiting | University of Miami | 35 | 2026-08-31 | 2026-07-22 |
| AIM-TEST: Microbiome-Targeted Nutrition for Functional Secondary Hypogonadism Fixed-Formula Microbiome-Targeted Oral Nutritional Supplement, Matched Oral Placebo - Hypogonadism, Male, Secondary Hypogonadism | Not applicable | Enrolling by invitation | Varol TUNALI | 112 | 2026-08-15 | 2026-09-29 |
| Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men Testosterone Cypionate Injection 200 mg/mL - Hypogonadism, Male | Phase 4 | Not yet recruiting | Azurity Pharmaceuticals | 144 | 2026-02-01 | 2026-01-09 |
| EndoPAT Device for Endothelial Dysfunction in ED Daily low-dose PDE5 inhibitor therapy, Testosterone therapy as per clinical guidelines. - Erectile Dysfunction, Hypogonadism, Male | Not applicable | Recruiting | University of California, Irvine | 120 | 2025-08-13 | 2026-02-02 |
| TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation Testosterone Replacement Therapy - Hypogonadism, Male, End Stage Renal Disease (ESRD) | Phase 1 / Phase 2 | Active not recruiting | University of California, Los Angeles | 50 | 2025-07-01 | 2025-12-17 |
| Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes Stem cells - Gonadal Dysfunction, Gonadal Failure | Recruiting | Jumeirah American Clinic | 60 | 2025-04-08 | 2025-04-10 | |
| 52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism Testosterone enanthate - Hypogonadism, Male | Phase 3 | Recruiting | Halozyme Therapeutics | 100 | 2025-03-07 | 2026-02-18 |
| ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer Alectinib, Brigatinib, Lorlatinib 100 mg - NSCLC Stage IV, Sex Disorder | Unknown | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 80 | 2024-08-05 | 2024-08-09 | |
| Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17 Relugolix 120Mg Tab, Curcumin, Testosterone Undecanoate 237 MG Oral Capsule - Hypogonadism, Male | Phase 1 / Phase 2 | Unknown | University of Washington | 10 | 2024-06-01 | 2024-03-15 |
| The Effects of Natesto For Treatment Of Hypogonadism Natesto Nasal Product - Hypogonadism, Male, Infertility, Male | Early Phase 1 | Withdrawn | Baylor College of Medicine | 2024-03-01 | 2024-04-24 | |
| Exploring the Relationship Between Androgen Metabolism, Metabolic Disease and Skeletal Muscle Energy Balance in Men Testosterone, GnRH - Hypogonadism, Male, Testosterone Deficiency | Unknown | Royal College of Surgeons, Ireland | 60 | 2023-03-12 | 2023-03-17 | |
| Physical Exercise as a Sustainability Tool in Men With Dysmetabolic Hypogonadism Structured and personalized program of physical exercise - Hypogonadism, Male, Metabolic Syndrome | Not applicable | Unknown | Istituto Auxologico Italiano | 72 | 2023-01-11 | 2024-03-12 |
| Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors Lipid profile, Coronary artery assessment, Hormone levels for hypogonadism - Testicular Cancer, Survivorship | Recruiting | Indiana University | 150 | 2022-10-11 | 2026-07-27 | |
| Natesto Spermatogenesis Reboot NatestoTM - Hypogonadism, Male | Phase 4 | Completed | University of Florida | 13 | 2022-06-01 | 2025-06-13 |
| Testosterone Treatment in Men With Chronic Kidney Disease Jatenzo Pill - Hypogonadism, Male, Kidney Disease, Chronic | Phase 2 | Recruiting | St. Louis University | 20 | 2022-03-15 | 2026-04-30 |
| Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Overweight/Obese Men With T2DM or Prediabetes and Hypogonadism Testosterone Undecanoate, Placebo - Fatty Liver, Overweight/Obesity | Phase 4 | Recruiting | Alexandra Kautzky-Willer | 32 | 2022-01-25 | 2024-03-13 |
| Perioperative Testosterone Replacement Therapy in Sarcopenic Male Colorectal Cancer Patients Testosterone - Colorectal Cancer, Sarcopenia | Unknown | London North West Healthcare NHS Trust | 30 | 2022-01-15 | 2022-05-10 | |
| Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism Testosterone Undecanoate 250 MG/ML, Placebo - Opioid Use, Pain | Phase 2 | Recruiting | Brigham and Women's Hospital | 150 | 2022-01-10 | 2026-07-27 |
| A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial Letrozole 2.5mg, hCG, Placebo - Hypogonadism, Hypogonadism, Male | Phase 4 | Terminated | Copenhagen University Hospital, Rigshospitalet | 8 | 2021-11-24 | 2024-02-15 |
Showing 20 of 48. Sign in to see all of them.
Eunuchism (48) · Hypogonadism (16) · Erectile Dysfunction (4) · Infertility, Male (3) · Metabolic Syndrome (3) · Obesity (3) · Azoospermia (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Endocrine System Diseases (2) · Gonadal Disorders (2) · Non-alcoholic Fatty Liver Disease (2) · Prostatic Neoplasms (2) · Acquired Immunodeficiency Syndrome (1) · Adrenal Insufficiency (1)
Endocrine System Diseases (46) · Gonadal Disorders (46) · Hypogonadism (32) · Male Urogenital Diseases (13) · Urogenital Diseases (13) · Genital Diseases (11) · Genital Diseases, Male (11) · Pathological Conditions, Signs and Symptoms (9) · Neoplasms (6) · Neoplasms by Site (6) · Nutritional and Metabolic Diseases (6) · Signs and Symptoms (6) · Glucose Metabolism Disorders (5) · Metabolic Diseases (5) · Digestive System Diseases (4)
Testosterone (8) · Testosterone Propionate (7) · testosterone undecanoate (7) · testosterone 17 beta-cypionate (4) · Chorionic Gonadotropin (2) · Clomiphene (2) · Natesto (2) · Anastrozole (1) · Atorvastatin (1) · Carboplatin (1) · Curcumin (1) · Drug Evaluation (1) · Gels (1) · Gonadotropin-Releasing Hormone (1) · LHRH, Ac-Nal(1)-Cpa(2)-Trp(3)-Arg(6)-Ala(10)- (1)
Lipocine Inc. (3) · University of Miami (3) · GlaxoSmithKline (2) · Marius Pharmaceuticals (2) · Seattle Institute for Biomedical and Clinical Research (2) · ANDROFERT - Clinica de Andrologia e Reproducao Humana (1) · Albany Medical College (1) · Alexandra Kautzky-Willer (1) · Azienda Ospedaliero-Universitaria di Modena (1) · Azurity Pharmaceuticals (1) · Baylor College of Medicine (1) · Brigham and Women's Hospital (1) · Cairo University (1) · Clarus Therapeutics, Inc. (1) · Comenius University (1)
United States (24) · Italy (3) · Brazil (2) · Denmark (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Austria (1) · Egypt (1) · Ireland (1) · Slovakia (1) · Tunisia (1) · United Arab Emirates (1)
Ranjith Ramasamy, MD (3) · Anthony DelConte, MD (2) · Om Dhingra, PhD (2) · Abraham Morgentaler, MD (1) · Alastair Smith, MB, ChB (1) · Aleksander Giwercman, MD (1) · Alexandra Kautzky-Willer, MD (1) · Alistair Smith, MB, ChB (1) · Anthony Delconte, MD (1) · Barbara Sahlin, MSc (1) · Bruce Kava, MD (1) · Caroline Michaela Kistorp, professor, MD (1) · Daniela Lucini, MD, PhD (1) · David Hernandez (1) · Faysal A Yafi, MD (1)
PMID 38606384, PMID 10664066, PMID 18567642, PMID 22783306, PMID 23533227, PMID 24344218, PMID 31492775, PMID 34191621, PMID 34994093, PMID 37126399, PMID 38591370, PMID 38764377, PMID 38852333, PMID 38909671
2017 (1)